Inventiva IVEVF
NASDAQ IVEVF
$3.59 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Inventiva (IVEVF) Total Non-Current Liabilities (2018 - 2025)

Inventiva (IVEVF) posted Total Non-Current Liabilities of $233.6 million for Q4 2025, up 59.45% on a QoQ basis from $146.5 million in Q2 2025, and up 108.4% year-over-year from $112.1 million in Q4 2024.

Analysis

Inventiva (IVEVF) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends

Inventiva has reported Total Non-Current Liabilities for 8 years, with the latest figure at $233.6 million in Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 108.4% year-over-year to $233.6 million in Q4 2025; TTM through Dec 2025 was $233.6 million, a 108.4% increase from a year earlier, with the FY2025 full-year figure at $233.6 million, up 108.4% from the prior year.
  • Total Non-Current Liabilities was $233.6 million for Q4 2025 at Inventiva, up from $146.5 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $233.6 million in Q4 2025, with the low at $11.7 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $69.9 million, with a median of $44.3 million recorded in 2023.
  • The largest YoY upside for Total Non-Current Liabilities was 745.32% in 2021 against a maximum downside of 28.62% in 2021.
  • Over 5 years, Total Non-Current Liabilities stood at $11.7 million in 2021, then surged by 245.99% to $40.6 million in 2022, then soared by 36.19% to $55.3 million in 2023, then surged by 102.53% to $112.1 million in 2024, then soared by 108.4% to $233.6 million in 2025.
  • The last three Total Non-Current Liabilities figures came in at $233.6 million (Q4 2025), $146.5 million (Q2 2025), and $112.1 million (Q4 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 646.71 Bn 625.95 Bn 17.26 Bn 105.99 Bn
2 AbbVie 442.22 Bn 435.65 Bn 12.70 Bn 106.45 Bn
3 Merck 366.92 Bn 359.78 Bn 12.21 Bn 16.16 Bn
4 Novartis Ag 266.90 Bn 259.21 Bn 11.24 Bn 48.34 Bn
5 Pfizer 159.20 Bn 147.50 Bn 10.94 Bn 100.86 Bn
6 Sanofi 52.44 Bn 45.06 Bn 10.79 Bn 32.04 Bn
7 Revolution Medicines 44.11 Bn 44.11 Bn - 1.53 Bn
8 Incyte 25.38 Bn 20.85 Bn 1.57 Bn 1.40 Bn
9 United Therapeutics 21.50 Bn 18.84 Bn 683.80 Mn 607.80 Mn
10 Inventiva 693.72 Mn 693.72 Mn - 233.57 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 233.57 Mn
Jun 30, 2025 146.48 Mn
Dec 31, 2024 112.08 Mn
Jun 30, 2024 75.75 Mn
Dec 31, 2023 55.34 Mn
Jun 30, 2023 44.31 Mn
Dec 31, 2022 40.63 Mn
Jun 30, 2022 15.60 Mn
Dec 31, 2021 11.74 Mn
Jun 30, 2021 16.65 Mn
Mar 31, 2021 16.76 Mn
Dec 31, 2020 16.45 Mn
Jun 30, 2020 1.97 Mn
Dec 31, 2019 1.89 Mn
Dec 31, 2018 3.58 Mn